fbpx

Veloxis announces tentative approval of Envarsus® XR FDA states that approval will not be final until Astagraf XL® exclusivity expires; Veloxis is appealing this decision

Veloxis disagrees that exclusivity for Astagraf XL, which was not identified as a listed drug or relied upon to support approval of Envarsus XR, should require delay in the formal approval of Envarsus XR.  Veloxis plans to immediately appeal this decision within FDA, and will pursue all options available to it.

The tentative approval notification received from FDA included agreement with manufacturing post-marketing commitments as previously proposed by Veloxis during NDA review as well as agreement on final labeling for the product.  There were no other conditions attached to the NDA approval.

For more information, please contact:

Veloxis Pharmaceuticals A/S
William J. Polvino                                              
President & CEO                                    
Tel: +1 732 321 3202                     
Email: wjp@veloxis.com   
                   
About Veloxis Pharmaceuticals
Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis’ unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit www.veloxis.com.

News

Seven research institutions receive DKK 20 million for coronavirus research
1. April 2020
How we handle changes to research projects in light of the coronavirus pandemic
31. March 2020
Lundbeck Foundation gives its first coronavirus grant to trial with a known drug
26. March 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge